Johnson & Johnson is reportedly set to acquire Intra-Cellular Therapies for around $10 billion.

Johnson & Johnson is reportedly in talks to acquire Intra-Cellular Therapies for around $10 billion, focusing on the latter's treatments for central nervous system disorders. The potential deal could be finalized as soon as this week, marking J&J's return to major acquisitions following a 2024 slump in healthcare transactions. Intra-Cellular's shares have risen about 40% in the last year.

2 months ago
45 Articles

Further Reading